EMA SAYS INGESTIBLE SENSOR CAN BE USED AS TRIAL BIOMARKER
March 1st, 2016
THE EUROPEAN Medicines Agency (EMA) has said that an ingestible sensor system developed by US-based pharmaco Proteus Digital Health can be used as a biomarker measuring patient adherence to medication in clinical trials. EMA’s committee for medicinal products for human use (CHMP) has said the technology is a “qualified method” for achieving this goal. Its assessment noted how the Proteus system can be “co-formulated with active pharmaceutical compounds into drug/device combinations, integrating measuring of medication adherence into oral ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.